OncoMed Pharmaceuticals, Inc.
OMED
OMED was delisted on the 22nd of April, 2019.
53 hedge funds and large institutions have $66.3M invested in OncoMed Pharmaceuticals, Inc. in 2013 Q3 according to their latest regulatory filings, with 53 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$19.6M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$7.26M |
| 3 |
CII
CR Intrinsic Investors
Stamford,
Connecticut
|
+$5.01M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$4.98M |
| 5 |
Primecap Management
Pasadena,
California
|
+$4.53M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
51
Tower Research Capital (TRC)
New York
| $3K | +$3.71K | +200 | New |
|
52
AllianceBernstein
Nashville,
Tennessee
| $1K | +$1.35K | +73 | New |
|
53
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $3 | +$3.28K | +177 | New |
|
OMED Hedge Fund Activity: Q3 2013 in Review
53 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q3 2013, worth a combined $66.3M.
Buyers outnumbered sellers: 53 funds opened new OMED positions and 0 closed out — a net gain of 53 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Sectoral Asset Management, opening a new position worth an estimated $19.6M.
- 53 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q3 2013, up from 0 in Q2 2013.
- Funds reported $66.3M of OncoMed Pharmaceuticals, Inc. stock for Q3 2013.
- 53 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q3 2013 and 0 closed out, a net change of +53 holders.
- The largest OncoMed Pharmaceuticals, Inc. buyer in Q3 2013 was Sectoral Asset Management, an estimated $19.6M added.
Based on aggregated 13F filings for Q3 2013.